Reece Armstrong

3 weeks ago | ddw-online.com | Reece Armstrong

Salma Jalal, Market Development Manager at Refeyn looks at the need for and challenges of measuring antibody aggregation and discusses the ideal requirements of analytical tools to support it. Antibody therapies have cemented their place in modern healthcare, offering powerful, targeted treatments for cancers, autoimmune disorders, infectious diseases and beyond.

3 weeks ago | ddw-online.com | Reece Armstrong

Hosted by Drug Discovery World and sponsored by The Jackson Laboratory, register now for the DDW ‘Turning Science into Business’ AI & ML summit: Navigating AI-driven drug discovery, to learn about the areas of opportunity for AI & ML in the drug discovery sector. Taking place on 30 April, 7am PDT / 10am EDT / 3pm BST / 4pm CEST, this free event will see experts and thought leaders in AI describe the latest research and applications that are driving the drug discovery process.

3 weeks ago | ddw-online.com | Reece Armstrong

Miguel Tam, Director of Strategic Marketing at Revvity’s BioLegend, explores the future directions and applications of flow cytometry in drug discovery, highlighting the opportunities it presents and the challenges that lie aheadFlow cytometry has long been a cornerstone in biomedical research and clinical diagnostics, offering unparalleled capabilities to analyse multiple parameters of single cells in a high-throughput manner.

3 weeks ago | ddw-online.com | Reece Armstrong

Sam Tomlinson, Vice President of Global Drug Safety at Arriello unpacks North America/EU research which compares today’s commercialisation strategies with those of five years ago.  As biotechs around the world look to new territories including emerging markets for their next returns, many are encountering unexpected hurdles. Too often, there is a significant gap between the envisaged opportunities and the practicalities and economics of accessing and converting them.

2 months ago | ddw-online.com | Reece Armstrong

Acacia Parks, PhD, MBA, Advisor to Lindus Health discusses the journey to commercialisation for digital therapeutics and how best to engage the FDA in this process. While there is no “one size fits all” approach to the development of any class of treatments, this is especially true for digital therapeutics (DTx). Being so new to the scene, their journey to commercialisation is not so clear-cut. Clinical trials for pharmaceuticals follow the traditional phased approach to achieve commercialisation.